阿卡波糖降低IGT个体及T2DM患者的心血管疾病危险

糖耐量减低(IGT)、2型糖尿病和心血管病变的发病和进展之间具有共同的病理生理学机制，而且是平行发展的。IGT阶段，餐后高血糖引发一系列不良反应，包括加重胰岛素抵抗、增强葡萄糖自氧化应激反应、加重内皮功能障碍和低度的血管炎症反应、降低动脉粥样硬化斑块稳定性等。糖尿病阶段，这一病变过程更加显著。阿卡波糖可阻断餐后血糖升高导致的胰岛素分泌功能障碍和胰岛素抵抗。此外，阿卡波糖还可以控制体重、降低血脂等心血管危险因子，改善血液高凝倾向，有助于心血管事件的防治。     

阿卡波糖治疗2型糖尿病餐后高血糖的初步临床观察

目的 观察阿卡波糖和达美康对２型糖尿病（ＤＭ）患的餐后２ｈ血糖的疗效及副作用。方法 老年２型ＤＭ患７６例,随机分为２组,阿卡波糖组（Ａ组）用达美康８０ －２４０ｍｇ／天,加阿卡波糖１００－３００ｍｇ／天,非阿卡波糖组（Ｂ组）单用达美康８０－２４０ｍｇ／天,检测治疗前后空腹血糖及餐后２ｈ血糖。结果 Ａ组２型ＤＭ患餐后２ｈ血糖大幅下降,从１５．１２±２．３２降至１０．０４±１．０４,而Ｂ组餐后２     

阿卡波糖治疗2型糖尿病餐后高血糖疗效观察

2003-2004年,我院用阿卡波糖治疗2型糖尿病餐后高血糖60例,疗效满意。现报告如下。     

阿卡波糖帮您消灭血管健康的大敌

餐后高血糖——血管健康的致命杀手糖尿病被称为冠心病的等危症,近80％的糖尿病患者最终死于心血管疾病．因此,糖尿病患者的血管健康是个非常关键的问题。     

阿卡波糖明显减少糖尿病人发生心梗的危险

MERIA研究是一个荟萃分析 ,包括 7个随机、双盲、安慰剂对照组研究 ,共有 2 180名 2型糖尿病人 ,治疗 4 10天。MERIA(MetaanalysisofRiskImprove mentunderAcarbose)是在预防非胰岛素依赖糖尿病研究 (STOP NIDDM )的基础上发展起来的。STOP NIDDM证明对糖耐量不好的病人 ,阿卡波糖能减少心血管事件 ,但对已经明显有糖尿病的病人 ,是否有同样效果 ,尚未得知。MERIA研究的终点是 :急性心梗、心绞痛、心衰、周围血管病、冠脉成型术、脑中风、心血管病死亡等。在阿卡波糖组 (n =12 4 8)中有76例 ,安慰剂组 (n =932 )有 88例。阿…     

二甲双胍和阿卡波糖治疗2型糖尿病餐后高血糖的疗效探讨

目的分析探究二甲双胍联合阿卡波糖治疗2型糖尿病餐后高血糖的疗效。方法该次将2018年3月-2019年3月该院收治的56例2型糖尿病患者利用随机数字表法将所有患者划分为两组,各28例;对照组实行常规方法治疗,观察组实行二甲双胍及阿卡波糖联合治疗,对比两组患者的血糖指标及用药不良反应发生率。结果①治疗前,两组空腹血糖及餐后2 h血糖均差异无统计学意义(P>0.05);治疗后,观察组上述两项血糖水平均明显低于对照组,两组数据差异有统计学意义(P<0.05)。②观察组用药不良反应发生率的3.57%,明显低于对照组的28.57%,两组数据差异有统计学意义(P<0.05)。结论2型糖尿病患者实行二甲双胍及阿卡波糖联合治疗的效果显著,能有效控制患者的餐后血糖及空腹血糖水平,用药安全性较高,值得在临床治疗领域中使用及推广。     

阿卡波糖(拜唐苹(R))在中国临床应用经验回顾及展望

作为第一个主要针对餐后血糖控制的降糖药,阿卡波糖(拜唐苹)在中国上市十几年来,得到医生和患者普遍认可,并且已经逐渐成为临床应用最广泛的口服降糖药之一.这与西方国家情况似有不同,是偶然因素还是另有原因?     

阿卡波糖对心血管疾病防治作用的研究进展

近年来,大量的研究表明糖耐量异常(impaired glucose tolerance,IGT)和2型糖尿病是心血管病变的等危症,而单纯严格控制血糖并不能有效地降低心血管疾病风险.α-糖苷酶抑制剂阿卡波糖具备预防IGT进展为2型糖尿病、降低IGT人群主要心血管事件发病率、心血管疾病发病率和病死率的作用.其作用机制除了控...     

阿卡波糖的降糖优势

阿卡波糖是通过延缓碳水化合物在肠道的吸收直接降低餐后血糖。此种独特的机制不仅单药治疗可有效降低糖化血红蛋白(HbA1c),疗效与磺脲类药物或二甲双胍相当,而且可安全有效地与其他降糖药联合使用。不仅如此,阿卡波糖在降低血糖的基础上,还具有以下独特的优势:     

Antioxidants and vitamins to reduce cardiovascular disease

Cardiovascular disease is the leading cause of morbidity and mortality in Western populations. Several lines of evidence support the role of oxidative stress in atherogenesis. Dietary micronutrients with antioxidant properties and vitamins have also been shown to have a benefit with regards to cardiovascular disease. The most persuasive evidence relates to alpha tocopherol and folate and vitamin B₁₂. Although the evidence is mounting for supplementation with alpha tocopherol and folate and B₁₂ for secondary prevention of cardiovascular disease, no clear consensus can be reached for primary prevention of cardiovascular disease. This will have to await results of ongoing clinical trials.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.     

糖耐量减低与心血管疾病及阿卡波糖作用

Impaired glucose tolerance(IGT) is a clinical state between normal and abnormal glucose metabolism with increased risk of cardiovascular disease. Its mechanism mainly related to insulin resistance, oxidative stress ,blood hypercoagulability, inflammatory response ,as well as related lipotoxieity. α-glucosidase inhibitor acarbose is safe and effective to reduce postprandial hyperglycemia, and has been approved for the treatment of patients with IGT. A growing number of studies have shown that acarbose also has cardiovascular benefit.